Señales en vivo de BMY | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	9.81M
Volumen promedio	15.91M
Capitalización de mercado	89.17B
EPS	$0 ( 2024-04-25 )
Próxima fecha de ganancias	( $1.680 ) 2024-07-25
Last Dividend	$0.600 ( 2024-01-04 )
Next Dividend	$0 ( N/A )
P/E	-14.19
ATR14	$0.0250 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Lenkowsky Adam	Sell	1 373	Market Share Units
2024-04-01	Shanahan Karin	Sell	3 306	Restricted Stock Units
2024-04-01	Shanahan Karin	Buy	3 306	Common Stock, $0.10 par value
2024-04-01	Shanahan Karin	Sell	1 196	Common Stock, $0.10 par value
2024-03-31	Yale Phyllis R	Buy	645	Deferred Share Units

INSIDER POWER
30.63
Last 100 transactions
Buy: 427 399 \| Sell: 226 852

Volumen Correlación

Largo: 0.57 (weak)

Corto: 0.74 (moderate)

Signal:(67.955) Neutral

Bristol-Myers Squibb Co Correlación

10 Correlaciones Más Positivas
UVV	0.926
AJAX	0.919
PYN	0.908
BSM	0.897
HLGN	0.892
BAK	0.89
HKIB	0.888
STZ	0.888
SDCI	0.886
WE	0.884

10 Correlaciones Más Negativas
IRL	-0.903
PANA	-0.883
IVH	-0.878
GOGN	-0.878
GOTU	-0.872
MGU	-0.871
ESM-UN	-0.871
STAR-PI	-0.869
HWKZ	-0.868
SGU	-0.866

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bristol-Myers Squibb Co Correlación - Moneda/Commodity

-0.41
( neutral )

-0.26
( neutral )

0.00
( neutral )

0.28
( neutral )

-0.02
( neutral )

Bristol-Myers Squibb Co Finanzas

Annual	2023
Ingresos:	$45.01B
Beneficio Bruto:	$34.31B (76.24 %)
EPS:	$3.88

FY	2023
Ingresos:	$45.01B
Beneficio Bruto:	$34.31B (76.24 %)
EPS:	$3.88

FY	2022
Ingresos:	$46.16B
Beneficio Bruto:	$36.02B (78.04 %)
EPS:	$2.97

FY	2021
Ingresos:	$46.39B
Beneficio Bruto:	$36.45B (78.57 %)
EPS:	$3.25

Financial Reports:

No articles found.

Bristol-Myers Squibb Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.540 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.600 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bristol-Myers Squibb Co Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.65 - average (55.60%) | Divividend Growth Potential Score: 1.214 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00892	1972-07-26
Last Dividend	$0.600	2024-01-04
Next Dividend	$0	N/A
Payout Date	2024-02-01
Next Payout Date	N/A
# dividends	206	--
Total Paid Out	$44.07	--
Avg. Dividend % Per Year	2.48%	--
Score	4.52	--
Div. Sustainability Score	5.65
Div.Growth Potential Score	1.214
Div. Directional Score	3.43	--

Next Divdend (Est)
(2024-08-12)

$0.605 Estimate 60.24 %

Dividend Stability

0.96 Excellent

Dividend Score

4.52

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.0178	0.95%
1973	$0.0482	2.36%
1974	$0.0452	3.25%
1975	$0.0491	3.23%
1976	$0.0536	2.60%
1977	$0.0655	3.24%
1978	$0.0725	3.64%
1979	$0.0856	4.04%
1980	$0.0714	3.31%
1981	$0.106	3.50%
1982	$0.121	3.85%
1983	$0.174	4.36%
1984	$0.190	3.71%
1985	$0.224	3.67%
1986	$0.214	2.74%
1987	$0.250	2.49%
1988	$0.519	5.04%
1989	$0.483	4.57%
1990	$0.521	3.84%
1991	$0.593	3.74%
1992	$0.492	2.34%
1993	$0.685	4.34%
1994	$0.871	6.37%
1995	$0.528	3.80%
1996	$0.893	4.38%
1997	$0.728	2.86%
1998	$0.557	1.24%
1999	$0.820	1.32%
2000	$0.932	1.52%
2001	$1.061	1.56%
2002	$1.400	2.75%
2003	$1.120	4.66%
2004	$0.840	2.86%
2005	$1.120	4.40%
2006	$1.120	4.82%
2007	$1.120	4.25%
2008	$1.550	5.93%
2009	$1.250	5.23%
2010	$0.960	3.75%
2011	$1.320	4.97%
2012	$1.360	3.88%
2013	$1.760	5.38%
2014	$1.450	2.77%
2015	$1.490	2.50%
2016	$1.140	1.70%
2017	$1.560	2.62%
2018	$1.600	2.61%
2019	$1.640	3.13%
2020	$2.29	3.62%
2021	$1.470	2.39%
2022	$2.16	3.49%
2023	$2.28	3.16%
2024	$0.600	1.14%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.135	1.500	-2.70	-4.05	[0 - 0.5]
returnOnAssetsTTM	-0.0621	1.200	-2.07	-2.48	[0 - 0.3]
returnOnEquityTTM	-0.230	1.500	-3.67	-5.50	[0.1 - 1]
payoutRatioTTM	-0.774	-1.000	-7.74	7.74	[0 - 1]
currentRatioTTM	1.110	0.800	9.45	7.56	[1 - 3]
quickRatioTTM	0.919	0.800	9.30	7.44	[0.8 - 2.5]
cashRatioTTM	0.361	1.500	9.10	10.00	[0.2 - 2]
debtRatioTTM	0.580	-1.500	0.338	-0.507	[0 - 0.6]
interestCoverageTTM	10.69	1.000	7.15	7.15	[3 - 30]
operatingCashFlowPerShareTTM	6.78	2.00	7.74	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.18	2.00	6.91	10.00	[0 - 20]
debtEquityRatioTTM	3.48	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.757	1.000	0.715	0.715	[0.2 - 0.8]
operatingProfitMarginTTM	0.306	1.000	5.88	5.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.239	1.000	9.78	9.78	[0.2 - 2]
assetTurnoverTTM	0.460	0.800	-0.268	-0.214	[0.5 - 2]
Total Score				5.65

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-14.47	1.000	-1.563	0	[1 - 100]
returnOnEquityTTM	-0.230	2.50	-2.36	-5.50	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.18	2.00	7.94	10.00	[0 - 30]
dividendYielPercentageTTM	5.32	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.78	2.00	7.74	10.00	[0 - 30]
payoutRatioTTM	-0.774	1.500	-7.74	7.74	[0 - 1]
pegRatioTTM	-0.0365	1.500	-3.58	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.301	1.000	4.96	0	[0.1 - 0.5]
Total Score				1.214

Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.